See you at a nickle!
Yes. Please leave. We’d love that.
Any day. I assume you will see a influx of volume come in when it’s done. If they want to keep adding assets and push it out a few more weeks, then I’m fine with that.
i guess no volume is good volume as long as not hitting bids.
Any idea as to when audit complete?
Why do you need volume right now? Just be happy that they are making tons of deals and there is 0 dilution. I pray there is 0 volume until uplist application.
what new auditor? whos's the new one vs the old one?
New auditor. New asssets. Any day now.
so what years audit is this thing waiting on? back in shareholders letter in august of 2021 they said 6 to 8 weeks audit would be complete. so here we are 2 years later. I am non bias and dont need to hear the horseshit just anyone who can fill me in on exactly what years we are waiting to be filed.
This has been the same ol' speech for years now... When the audit is done then comes the uplist! .. Still hasn't happened.. Waiting and waiting and waiting...
Audit should be done any day now. Some big deals announced on that PR last week.
They are applying to a higher exchange once they get the audit. The price will need to be $2-$4 to uplist. That’s why you will have the buying come in from the millionaires backing the company.
How close to audit completion? Then what? Why move after completion. There are no buyers and not sure if this helps. Hope I'm wrong.
Not a big position but holding longer term..
Nice Rafa move today
No clue who Birdman is. But this is a great buying opportunity as the short knows there’s still a few more weeks before the audit comes out, so they are holding it down and trying to cover.
I hope you're right! Really do. Otherwise, there are a bunch of people that will lose tons of money with the birdman yet again!
More like 99% chance. They literally are almost done with the construction of like a $20 million facility in Uzbekistan and have massive contracts with China & Bebig medical out of Germany. There’s been 0 dilution and they are still paying big $$$ per quarter to keep financials current. Just paid OTC markets too.
My bet is the new auditor (who probably cost $1 million +) is just about finished and then it’s go time.
this is a dead stock 1% chance we see it come back from the dead
Not really. 0 dillution in 5 years and still making $20 million per year. The Pharma park building is near operational and that new Chinese contract will be huge.
Pred never made money and diluted non-stop. I’d stop comparing the two.
On please. You’re just watching a short drive the stock down and cover over and over again. The company just paid $5k to get back on pink sheets and re-filed financials. They are now current and yield sign gone. Zero shares diluted in 5 years. So that’s about legit as it gets.
Sorry, wish I could help you either way. I try to determine the downside risk and the upside potential. I believe Rafa is a long term buy now. I just do not have a sense of urgency to purchase shares with too much unknown.
i'm starting to get really skeptical about this stock. Twitter releases just don't cut it.
Have not yet bought back in to Rafa....
I bought IFUS .005 ...currently much higher
You are correct. 1 Step closer!
Nice! Yield sign should come off now. ??
No clue. I see a bunch of the same people in a lot of the same tickers on Twitter. Maybe he is part of them? Is he on Twitter?
You know who the Birdman is since you have posted are most of his gems. It not good to fool Mother Nature. Tsk Tsk. How's that working out for you.
No clue what Bird man is.
So you’re saying their whole ploy was to build a huge multi-million Uzbekistan medical building. (Which is real and listed on Uzbekistan government websites) and then come out with $20 million in gross profits each year and never ever dilute or sell off any shares?
Or is it more plausible that they are re-auditing new assets that have been relocated out of war torn countries?
You have no way to actually know this. None. The cash figure may as well be ZERO. Remember, Twitter posts don't count, unaudited financials don't count, and neither do crazy Bird Man updates.
RAFA was a Bird Man stock, so it is doomed !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Many OTC stocks are easily overlooked because they don't get the coverage of peers traded on national exchanges and consequently very few investors have the opportunity to know about them. A perfect example is the recent closing of a reverse merger increasing sales by over 700% and adding sizable international operations of private Biocogency into Rafarma Pharmaceuticals (OTC: RAFA) where the RAFA share price has not yet reflected the new added value.
On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price is expected to begin climbing to more fair and reasonable market valuations that could exceed expectations.
About Rafarma Pharmaceuticals
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.
Biocogency owns PJSC "Krasfarma", the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.
The Company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.
A rich history is not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.
Safe and effective generic medicines of PJSC "Kraspharma", which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.
Today PJSC "Kraspharma" is the Eastern Europe and Russia undisputed leader in the production of:
Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the Government of the Russian Federation.
The products of PJSC "Kraspharma" are sold in Russia, Eastern Europe, Central Asia and in the countries of the Asia-Pacific region.
What Biocogency Adds to Rafarma
This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.
The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia's largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of a variety of products including packaging goods, materials for microelectronics and photo materials, are both steeped in corporate history going back half a century or more in Russia.
Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.
What's in it for RAFA? An Immediate Spike in Revenue and Profits
The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.
Those results are going to get an immediate shot of adrenaline.
During fiscal 2019, the Biocogency group reported unaudited consolidated earnings of $73 million and gross profits of $17 million. As a course of becoming fully reporting and planning to uplist, the financial results are being audited and adjusted to meet GAAP standards.
Using the results from 2019, it is easy to extrapolate pro forma revenue of $84.4 million and gross profit of $20.3 million for the combined company. It is those type of financials that will underpin a move to the Nasdaq or NYSE.
More on how the price to sales ratio stacks up to industry comps are discussed here. Several Pharmaceutical market comps point to Rafarma share prices that are many multiples higher than the current price of $1.69.
When it comes to value, it certainly bears mentioning the investments that Biocogency has put into its pipeline and platforms since 2012, which management pegs at more than $120.0 million. Much of this investment has been directed by Shpurov since he bought the Kraspharma during the outbreak of the global financial collapse in 2008 for the purpose of restoring and expanding production volumes post-recession while establishing a high-tech GMP pharmaceutical manufacturer in Krasnoyarsk.
That was accomplished. Today, Kraspharma is a leading producer of wide swath of generic drugs and pharma products spanning antibiotics, blood substitutes, infusion solutions, tuberculosis and preparations for other pharmacological groups. Sales channels extend throughout Russia, Eastern Europe and the Asia-Pacific region.
Widening the Footprint
The plan is for vertical growth by expanding the existing channels while leveraging RAFA relationships for horizontal growth through entering the lucrative North American markets.
In fairness, Russia alone can be a company maker. A huge net importer of medicine, the Russian government is pushing for national security in the supply chain as outlined in the Pharma 2030 Strategy. With that in mind, Statista forecasts the Russian pharmaceutical industry will grow 147% between 2017 and 2030.
During Q1, the Russian pharma market surged 125% year-over-year to about 320 billion Russian rubles (US$4.2 billion). Generic drugs typically dominate the prescription market, accounting for 64.5% of the category in 2017, meaning Kraspharma is in a strong position.
Given the sheer volume of people, Asia is another tremendous market. The Rx market in China alone is forecast to reach $160 billion by 2022, highlighting the market opportunity. With respect to the Asian drug development market, ResearchAndMarkets estimates 6.54% compound annual growth to reach $62.46 billion by 2026.
Still, the U.S. is the Holy Grail as the biggest pharmaceutical market in the world, weighing in at a whopping $484.4 billion in 2018.
With the reverse merger now closed, the newly created Rafarma Pharmaceuticals that now boasts fast-growing operations well in excess of $100 million for 2019 is decidedly undervalued when compared to industry valuations for similar companies. Management plans for uplisting and higher investor awareness programs are soon in the future which will help bring the Rafarma opportunity to the forefront resulting in substantially higher prices and trading volume.
The current price has not yet appreciated to reflect the newly increased sales and valuations and therefore presents an opportunity to astute investors who act now before the story becomes more commonly known.